-
The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHEREDewan P, Jackson A, Jhund PS et al. -
Dilated cardiomyopathy: so many cardiomyopathies!G Sinagra, PM Elliott, M Merlo et al.
-
Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 InhibitorsS Verma, S Rawat, KL Ho et al.
-
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesWriting Committee Members, PA Heidenreich, B Bozkurt et al.
-
Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-AnalysisW Masson, A Lavalle-Cobo, JP Nogueira et al.
-
Longitudinal Change in Galectin-3 and Incident Cardiovascular OutcomesA Ghorbani, V Bhambhani, RH Christenson et al.
-
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-ReducedF Zannad, JP Ferreira, SJ Pocock et al.
-
Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failureNR Pugliese, F Paneni, M Mazzola et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
